Pharmacologic Options for Insomnia Treatment
For chronic insomnia in adults, use benzodiazepine receptor agonists (eszopiclone, zaleplon, zolpidem), low-dose doxepin (3-6 mg), ramelteon (8 mg), or orexin receptor antagonists (suvorexant, daridorexant, lemborexant) as evidence-based options, while avoiding trazodone, diphenhydramine, melatonin, and benzodiazepines for long-term use. 1
Evidence-Based Medication Classes
Recommended Agents
The 2017 American Academy of Sleep Medicine guidelines provide the most comprehensive framework for pharmacologic treatment 1:
For Sleep Onset Insomnia:
- Zaleplon 10 mg - specifically targets difficulty falling asleep 1
- Triazolam 0.25 mg - short-acting benzodiazepine option 1
- Ramelteon 8 mg - melatonin receptor agonist with favorable safety profile 1
- Eszopiclone 2-3 mg - also effective for sleep maintenance 1
- Zolpidem 10 mg - also effective for sleep maintenance 1
For Sleep Maintenance Insomnia:
- Doxepin 3-6 mg - low-dose tricyclic antidepressant, particularly effective for middle-of-night awakenings 1
- Suvorexant 10-20 mg - orexin receptor antagonist 1
- Eszopiclone 2-3 mg 1
- Zolpidem 10 mg 1
- Temazepam 15 mg - also effective for sleep onset 1
Newer Orexin Receptor Antagonists:
Recent evidence supports daridorexant and lemborexant as effective options with favorable long-term profiles 2, 3, 4. These agents inhibit wakefulness rather than induce sedation, have demonstrated efficacy over 12 months, show no evidence of rebound insomnia or withdrawal, and have minimal abuse potential 2.
Agents NOT Recommended
The guidelines explicitly recommend against the following 1:
- Trazodone 50 mg - insufficient evidence of benefit
- Diphenhydramine - antihistamine with unfavorable risk profile
- Melatonin 2 mg - inadequate efficacy data
- Tiagabine - anticonvulsant with harms outweighing benefits
- L-tryptophan
- Valerian
Critical Safety Considerations
Benzodiazepine and Z-Drug Warnings
The FDA labeling for nonbenzodiazepine hypnotics warns of 5:
- Daytime memory and psychomotor impairment
- Abnormal thinking and behavioral changes
- Complex behaviors (sleep-driving without recollection)
- Depression and suicidal ideation
- Observational data links hypnotics to dementia (hazard ratio 2.34) 5
Duration of Treatment
Benzodiazepines and benzodiazepine receptor agonists should be limited to ≤4 weeks 3. Longer-term use requires careful individual risk-benefit assessment 3. Orexin receptor antagonists can be used for up to 3 months or longer in selected cases 3.
Dose Considerations
Many trials used doses exceeding FDA recommendations, particularly for women and older adults 5. Clinicians must adhere to FDA-approved dosing, especially in these populations.
Treatment Algorithm
Step 1: Identify insomnia subtype (sleep onset vs. maintenance vs. both)
Step 2: For sleep onset only:
- First choice: Zaleplon 10 mg or ramelteon 8 mg (better safety profile)
- Alternative: Zolpidem 10 mg or eszopiclone 2-3 mg
Step 3: For sleep maintenance only:
- First choice: Doxepin 3-6 mg or orexin antagonist (suvorexant, daridorexant, lemborexant)
- Alternative: Eszopiclone 2-3 mg
Step 4: For both sleep onset and maintenance:
- Eszopiclone 2-3 mg, zolpidem 10 mg, or temazepam 15 mg
- Consider orexin antagonist for longer-term need
Step 5: Plan for short-term use (≤4 weeks for BZRAs) with clear discontinuation strategy
Common Pitfalls to Avoid
Do not prescribe benzodiazepines for long-term insomnia management - the dementia risk and dependence potential outweigh benefits 5
Avoid diphenhydramine and other antihistamines - despite widespread OTC use, guidelines explicitly recommend against them due to next-day sedation, anticholinergic effects, and lack of efficacy evidence 1
Do not use trazodone off-label - despite common clinical practice, evidence shows harms outweigh benefits 1
Recognize the large placebo response - 24-48% of placebo patients show significant improvement on global measures, with 19-39 minute improvements in sleep parameters 5
Consider patient age and sex - FDA dosing differs for women and older adults; many study doses exceeded these recommendations 5
Prolonged-release melatonin (not immediate-release) may be considered for patients ≥55 years for up to 3 months 3, though immediate-release melatonin is not recommended 1
All recommendations carry WEAK strength in the AASM guidelines, reflecting that clinical judgment and patient preferences should guide final treatment selection 1. However, the evidence clearly distinguishes between agents with demonstrated efficacy versus those that should be avoided.